ENDO Highlights

Thyroid nodules arising in the isthmus are more likely to be malignant and demonstrate more aggressive behavior relative to thyroid nodules from either thyroid lobe. touchENDOCRINOLOGY were joined by Dr Sina Jasim (Washington University, St Louis, MO, USA) to discuss the main findings of her study presented at ENDO23. The abstract ‘THU-680 – Cytologic And […]

Extended-release formulations of the somatostatin analogues, octreotide and lanreotide, are first-line medical therapies for patients with acromegaly who have contraindications for, or are not cured by, surgical intervention and/or radiotherapy. touchENDOCRINOLOGY are joined by Dr Diego Ferone (University of Genova, Italy) to discuss the efficacy and safety of CAM2029 in acromegaly evaluated in a 6-month, […]

It was a pleasure to talk to Professor Camilo Jimenez (The University of Texas MD Anderson Cancer Center, Houston, TX) around biochemical tumour markers in the use of I-131-labeled MIBG for pheochromocytoma and paraganglioma. ‘Biochemical Tumor Marker Status and Its Role in Treatment Response in Patients Who Received High-Specific-Activity I-131 MIBG in Advanced Pheochromocytoma and […]

It was a pleasure to talk to Professor Camilo Jimenez (The University of Texas MD Anderson Cancer Center, Houston, TX) around biochemical tumour markers in the use of I-131-labeled MIBG in pheochromocytoma and paraganglioma. ‘Biochemical Tumor Marker Status and Its Role in Treatment Response in Patients Who Received High-Specific-Activity I-131 MIBG in Advanced Pheochromocytoma and […]

We were delighted to catch up with Dr Susan Samson (Mayo Clinic, Jacksonville, FL, US) to discuss the one-year outcomes of oral octreotide capsule use in patients with acromegaly. ‘One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly.‘ (PRESENTATION NUMBER: OR14-3) was presented at the […]

We were delighted to talk to Professor Claudia Fox (University of Minnesota, Minneapolis, MN, US) around the use of exenatide for weight loss maintenance among adolescents with severe obesity. ‘Once-Weekly Exenatide Enhances Weight Loss Maintenance in Adolescents with Severe Obesity: A Randomized, Placebo-Controlled Trial.‘ (PRESENTATION NUMBER: OR02-4) was presented at the ENDO 2021 Virtual Annual […]

It was a pleasure to talk to Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA, US) around the effect of once-weekly semaglutide on weight loss maintenance in overweight or obese adults. ‘Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4).‘ (PRESENTATION […]

We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease […]